Hive™ Stand-alone Anterior Lumbar Interbody System

K200541 · Hd Lifesciences, LLC · OVD · Apr 28, 2020 · Orthopedic

Device Facts

• Record ID: K200541
• Device Name: Hive™ Stand-alone Anterior Lumbar Interbody System
• Applicant: Hd Lifesciences, LLC
• Product Code: OVD · Orthopedic
• Decision Date: Apr 28, 2020
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 888.3080
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The HD LifeSciences Hive™ Stand-alone Anterior Lumbar Interbody System is indicated for use in skeletally mature patients with Degenerative Disc Disease (DDD) at one or two contiguous levels from L2-S1. DDD is defined as discogenic back pain with degeneration of the disc confirmed by patient history and radiographic studies. Patients should have received 6 months of non-operative treatment prior to treatment with the devices. These DDD patients may also have up to Grade I spondylolisthesis or retrolisthesis at the involved level(s). It is indicated to be used with autograft bone and allograft bone comprised of cancellous and/or corticocancellous bone. These devices are intended to be used with the screws which accompany the implants. When used with the accompanying screws, these devices may be used as stand-alone interbody devices. If the accompanying screws are not used the device is intended for use with supplemental fixation. Hyperlordotic implants (20° and greater lordosis) must be used with supplemental fixation (e.g. posterior fixation) that are cleared by the FDA for use in the lumbar spine.

Device Story

The Hive™ Stand-alone Anterior Lumbar Interbody System is an intervertebral body fusion device designed for spinal stabilization. It consists of additive-manufactured titanium cages, screws, and screw cover plates. The device is implanted by a surgeon during spinal fusion procedures to provide structural support and facilitate fusion in the lumbar spine (L2-S1). It functions as a stand-alone device when used with the provided screws or as an interbody spacer requiring supplemental fixation. The system is available in various geometries and lordotic configurations to match patient anatomy. By stabilizing the vertebral segment and maintaining disc space height, the device promotes bone fusion, thereby reducing discogenic back pain and improving spinal alignment. It is intended for use with autograft or allograft bone.

Clinical Evidence

Bench testing only. Testing included static and dynamic axial compression and compressive shear (ASTM F2077-18), static expulsion (ASTM Draft F-04.25.02.02), static subsidence (ASTM F2267-04), screw pullout (ASTM F543-17), cytotoxicity (ISO 10993-5), and bacterial endotoxins (ANSI/AAMI ST72:2019). Results demonstrate mechanical strength sufficient for intended use.

Technological Characteristics

Interbody fusion cages manufactured from Ti-6Al-4V titanium (ASTM F3001) via additive manufacturing. Screws and cover plates made from Ti-6Al-4V (ASTM F136). Modular design for stand-alone or supplemental fixation. Mechanical performance validated per ASTM F2077, F2267, and F543 standards.

Indications for Use

Indicated for skeletally mature patients with Degenerative Disc Disease (DDD) at one or two contiguous levels from L2-S1, including those with up to Grade I spondylolisthesis or retrolisthesis. Requires 6 months of failed non-operative treatment. Contraindicated for hyperlordotic implants (≥20°) without supplemental posterior fixation.

Regulatory Classification

Identification

An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.

Special Controls

*Classification.* (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval. (c) *Date premarket approval application (PMA) or notice of product development protocol (PDP) is required.* Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.

Predicate Devices

• HDLS Lumbar Interbody System (K170676)
• M3 Stand-alone Anterior Lumbar System (K180814)
• S128 ALIF System (K180502)
• Arco-SA Lumbar Cage System (K182195)

Submission Summary (Full Text)

{0}------------------------------------------------

April 28, 2020

Image /page/0/Picture/1 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which consists of a blue square with the letters "FDA" in white, followed by the words "U.S. FOOD & DRUG" in blue, and then the word "ADMINISTRATION" in a smaller font size.

HD LifeSciences LLC John Sullivan Director of Operations 12 Gill St Suite 4500 Woburn, Massachusetts 01801

Re: K200541

Trade/Device Name: Hive™ Stand-alone Anterior Lumbar Interbody System Regulation Number: 21 CFR 888.3080 Regulation Name: Intervertebral Body Fusion Device Regulatory Class: Class II Product Code: OVD, MAX Dated: March 2, 2020 Received: March 3, 2020

Dear John Sullivan:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for

{1}------------------------------------------------

devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely,

for

Brent Showalter, Ph.D. Assistant Director (Acting) DHT6B: Division of Spinal Devices OHT6: Office of Orthopedic Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

| DEPARTMENT OF HEALTH AND HUMAN SERVICES | Form Approved: OMB No. 0910-0120 |
|-----------------------------------------|-----------------------------------------------------------------|
| Food and Drug Administration | Expiration Date: 06/30/2020 |
| <b>Indications for Use</b> | See PRA Statement below. |
| 510(k) Number (if known) | K200541 |
| Device Name | Hive ^TM Stand-alone Anterior Lumbar Interbody System |
| Indications for Use (Describe) | |

The HD LifeSciences Hive^TM Stand-alone Anterior Lumbar Interbody System is indicated for
use in skeletally mature patients with Degenerative Disc Disease (DDD) at one or two
contiguous levels from L2-S1. DDD is defined as discogenic back pain with degeneration of the
disc confirmed by patient history and radiographic studies. Patients should have received 6
months of non-operative treatment prior to treatment with the devices. These DDD patients may
also have up to Grade I spondylolisthesis or retrolisthesis at the involved level(s). It is indicated
to be used with autograft bone and allograft bone comprised of cancellous and/or
corticocancellous bone. These devices are intended to be used with the screws which accompany
the implants. When used with the accompanying screws, these devices may be used as stand-
alone interbody devices. If the accompanying screws are not used the device is intended for use
with supplemental fixation.

Hyperlordotic implants (20° and greater lordosis) must be used with supplemental fixation (e.g.
posterior fixation) that are cleared by the FDA for use in the lumbar spine.

Type of Use (Select one or both, as applicable)

| <input checked="true" type="checkbox"/> Prescription Use (Part 21 CFR 801 Subpart D) | <input type="checkbox"/> Over-The-Counter Use (21 CFR 801 Subpart C) |
|--------------------------------------------------------------------------------------|----------------------------------------------------------------------|
|--------------------------------------------------------------------------------------|----------------------------------------------------------------------|

PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995. *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.* The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail] "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

| Submitter's Name | HD LifeSciences LLC |
|---------------------------|------------------------------------------------------------------|
| Submitter's Address | 12 Gill St<br>Suite 4500<br>Woburn, MA 01801 |
| Company Contact Person | John Sullivan<br>603-234-4321 |
| Contact Person | John Sullivan<br>603-234-4321<br>[e-mail] |
| Date Summary was Prepared | 3/2/20 |
| Trade or Proprietary Name | Hive™ Stand-alone Anterior Lumbar Interbody System |
| Common or Usual Name | Intervertebral Body Fusion Device |
| Classification | Class II per 21 CFR §888.3080 |
| Product Code | OVD, MAX |
| Classification Panel | Division of Orthopedic Devices |

#### 510(k) Summarv

# Description of the Device Subject to Premarket Notification:

The Hive™ Lumbar Interbody Fusion System is FDA cleared under K170676. This submission describes an addition to the Anterior IBFD configurations in which the device in combination with the provided screws would serve as a stand-alone interbody fusion device. This submission adds the Hive™ Stand-alone Anterior Lumbar Interbody System to the previously cleared system, which consists of interbody fusion cages made from Ti-6Al-4V implant-grade titanium conforming to ASTM F3001 using additive manufacturing technology. The implants of the Hive™ Stand-alone Anterior Lumbar Interbody System are offered in a variety of lengths, widths and cross-sectional geometries to accommodate patient anatomy and surgical approach. The implants of the Hive™ Stand-alone Anterior Lumbar Interbody System are also offered in various lordotic configurations to ensure proper stability and alignment of the spine for differing patient anatomy. Implants incorporate features for fixating the device to the vertebral body in a modular stand-alone manner using either interfixated features within the intervertebral space or outer plate fixation on the anterior surface of the vertebral bodies. Inter-fixation and outerfixation allow adjustable placement of fixation components utilizing screws and screw cover plates made from Ti-6A1-4V conforming to ASTM F136.

#### INDICATIONS FOR USE

The HD LifeSciences Hive™ Stand-alone Anterior Lumbar Interbody System is indicated for use in skeletally mature patients with Degenerative Disc Disease (DDD) at one or two contiguous levels from L2-S1. DDD is defined as discogenic back pain with degeneration of the disc confirmed by patient history and radiographic studies. Patients should have received 6 months of non-operative treatment prior to treatment with the devices. These DDD patients may also have up to Grade I spondylolisthesis or retrolisthesis at the involved level(s). It is indicated to be used with autograft bone and allograft bone comprised of cancellous and/or corticocancellous bone. These devices are intended to be used with the screws which accompany

{4}------------------------------------------------

the implants. When used with the accompanying screws, these devices may be used as standalone interbody devices. If the accompanying screws are not used the device is intended for use with supplemental fixation.

Hyperlordotic implants (20° and greater lordosis) must be used with supplemental fixation (e.g. posterior fixation) that are cleared by the FDA for use in the lumbar spine.

The indications for use for the Hive™ Stand-alone Anterior Lumbar Interbody System are similar to the predicates listed in Table 5-1.

## TECHNOLOGICAL CHARACTERISTICS

The subject and predicate devices have nearly identical technological characteristics and the minor differences do not raise any new issues of safety and effectiveness. Specifically the following characteristics are the same between the subject and predicates:

- Principle of Operation ●
- Indications for Use ●
- Materials of manufacture ●

#### Table 5-1: Predicate Devices

| 510k<br>Number | Trade or Proprietary or Model Name | Manufacturer | Predicate Type |
|----------------|---------------------------------------|-----------------|----------------|
| K170676 | HDLS Lumbar Interbody System | HD LifeSciences | Primary |
| K180814 | M3 Stand-alone Anterior Lumbar System | CoreLink | Additional |
| K180502 | S128 ALIF System | Renovis | Additional |
| K182195 | Arco-SA Lumbar Cage System | Neurostructures | Additional |

## PERFORMANCE DATA

The Lumbar Interbody System has been tested in the following test modes:

- Static axial compression per ASTM F2077-18
- Static compressive shear per ASTM F2077-18 ●
- . Dynamic axial compression per ASTM F2077-18
- Dynamic compressive shear per ASTM F2077-18 ●
- Static expulsion per ASTM Draft F-04.25.02.02 .
- . Static subsidence per ASTM F2267-04
- . Screw Pullout ASTM F543-17
- Cytotoxicity (MEM Elution) ISO 10993-5 .
- Bacterial endotoxins test per ANSI/AAMI ST72:2019 ●

{5}------------------------------------------------

The results of this testing battery show that the strength of the Hive™ Stand-alone Anterior Lumbar Interbody System is sufficient for its intended use and is substantially equivalent to legally marketed predicate devices.

### CONCLUSION

The overall technology characteristics and mechanical performance data lead to the conclusion that the Hive™ Stand-alone Anterior Lumbar Interbody System is substantially equivalent to predicate devices.